Viking Therapeutics, Inc. VKTX
- VK2735 — Obesity Phase 3
- VK2735 — Type 2 Diabetes Phase 3
- VK2735 — Obesity Phase 2
GIP receptor (1 companies · 3 programs)
Companies with an active program directed at GIP receptor.
Companies with an active program directed at GIP receptor.